133 related articles for article (PubMed ID: 6528087)
21. Hormone receptors. An update and application.
Hubay CA; Arafah B; Gordon NH; Guyton SP; Crowe JP
Surg Clin North Am; 1984 Dec; 64(6):1155-72. PubMed ID: 6393400
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant programs for postmenopausal women with node-positive breast cancer: preliminary analysis of 5-year results.
Rossi A; Brambilla C; Valagussa P; Bonadonna G
Recent Results Cancer Res; 1984; 96():178-83. PubMed ID: 6396772
[No Abstract] [Full Text] [Related]
23. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
24. Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach.
Gardin G; Rosso R; Campora E; Repetto L; Naso C; Canavese G; Catturich A; Corvò R; Guenzi M; Pronzato P
Eur J Cancer; 1995; 31A(9):1428-33. PubMed ID: 7577066
[TBL] [Abstract][Full Text] [Related]
25. Eight-year follow-up of adjuvant therapy for stage II breast cancer.
Hubay CA; Gordon NH; Pearson OH; Marshall JS; McGuire WL
World J Surg; 1985 Oct; 9(5):738-49. PubMed ID: 3904231
[No Abstract] [Full Text] [Related]
26. Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer.
Buzdar AU; Smith TL; Powell KC; Blumenschein GR; Gehan EA
Breast Cancer Res Treat; 1982; 2(2):163-9. PubMed ID: 6897369
[TBL] [Abstract][Full Text] [Related]
27. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer.
Buzdar AU; Kau SW; Smith TL; Hortobagyi GN
Am J Clin Oncol; 1989 Apr; 12(2):123-8. PubMed ID: 2705401
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
[TBL] [Abstract][Full Text] [Related]
30. [Adriamycin/cyclophosphamide: current standard in adjuvant therapy for breast carcinoma?].
Sauter C
Schweiz Med Wochenschr; 1994 Oct; 124(43):1879-81. PubMed ID: 7973513
[No Abstract] [Full Text] [Related]
31. Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED).
Buzdar AU; Blumenschein GR; Smith TL; Tashima CK; Hortobagyi GN; Yap HY; Gutterman JU; Hersh EM; Gehan EA
J Surg Oncol; 1979; 12(1):27-40. PubMed ID: 480951
[TBL] [Abstract][Full Text] [Related]
32. Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: seventy-two-month follow-up.
Hubay CA; Gordon NH; Crowe JP; Guyton SP; Pearson OH; Marshall JS; Mansour EG; Hermann RE; Jones JC; Flynn WJ
Surgery; 1984 Jul; 96(1):61-72. PubMed ID: 6740497
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.
Mouridsen HT; Rose C; Brincker H; Thorpe SM; Rank F; Fischerman K; Andersen KW
Recent Results Cancer Res; 1984; 96():117-28. PubMed ID: 6396765
[No Abstract] [Full Text] [Related]
34. Multimodal treatment of locoregionally advanced breast cancer.
Hortobagyi GN; Blumenschein GR; Spanos W; Montague ED; Buzdar AU; Yap HY; Schell F
Cancer; 1983 Mar; 51(5):763-8. PubMed ID: 6687377
[TBL] [Abstract][Full Text] [Related]
35. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
Wolowacz SE; Cameron DA; Tate HC; Bagust A
J Clin Oncol; 2008 Feb; 26(6):925-33. PubMed ID: 18281666
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
Mackey JR; Martin M; Pienkowski T; Rolski J; Guastalla JP; Sami A; Glaspy J; Juhos E; Wardley A; Fornander T; Hainsworth J; Coleman R; Modiano MR; Vinholes J; Pinter T; Rodríguez-Lescure A; Colwell B; Whitlock P; Provencher L; Laing K; Walde D; Price C; Hugh JC; Childs BH; Bassi K; Lindsay MA; Wilson V; Rupin M; Houé V; Vogel C;
Lancet Oncol; 2013 Jan; 14(1):72-80. PubMed ID: 23246022
[TBL] [Abstract][Full Text] [Related]
37. Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.
Livi L; Saieva C; Borghesi S; De Luca Cardillo C; Scotti V; Mangoni M; Greto D; Cataliotti L; Paiar F; Bianchi S; Biti GP
J Chemother; 2009 Nov; 21(5):558-65. PubMed ID: 19933048
[TBL] [Abstract][Full Text] [Related]
38. Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience.
Koh EH; Buzdar AU; Ames FC; Singletary SE; McNeese MD; Frye D; Holmes FA; Fraschini G; Hug V; Theriault RL
Cancer Chemother Pharmacol; 1990; 27(2):94-100. PubMed ID: 2249339
[TBL] [Abstract][Full Text] [Related]
39. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
[TBL] [Abstract][Full Text] [Related]
40. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy.
Hortobagyi GN; Ames FC; Buzdar AU; Kau SW; McNeese MD; Paulus D; Hug V; Holmes FA; Romsdahl MM; Fraschini G
Cancer; 1988 Dec; 62(12):2507-16. PubMed ID: 3056604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
